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Background Depression is a prevalent condition in pregnancy
affecting about 10% of women. Maternal depression has been
associated with an increase in preterm births (PTB), low birthweight
and fetal growth restriction, and postnatal complications. Available
treatments for depressive disorders are psychotherapeutic interventions
and antidepressant medications including selective serotonin inhibitors
(SSRIs). SSRI use during pregnancy has been associated with several
fetal and neonatal complications; so far, however, the risk of PTB in
women using SSRIs during pregnancy is still a subject of debate.
Objective To evaluate the risk of preterm birth (PTB) in cases of
exposure to SSRIs during pregnancy.
Search strategy Electronic databases (MEDLINE, Scopus,
ClinicalTrials.gov, the PROSPERO International Prospective
Register of Systematic Reviews, EMBASE and the Cochrane
Central Register of Controlled Trials) were searched from their
inception until May 2015 with the use of a combination of the
following text words ‘depression’, ‘pregnancy’, ‘exposure’,
‘antidepressant’, ‘SSRI’, ‘selective serotonin reuptake inhibitor’,
‘preterm birth’, ‘small for gestational age’ and ‘prematurity’.
Selection criteria We included studies evaluating the effect of
SSRIs exposure in utero and pregnancy outcomes. All cohort and
case-control studies were eligible to be included if they reported
the incidence of PTB after any exposure to SSRIs and had a
comparison group of unexposed pregnant women. Studies
without a control group were excluded.
Data collection and analysis The primary outcome was the
incidence of PTB <37 weeks. Subgroup analysis of studies in
which controls were defined as women with depression but
without SSRI exposure during pregnancy were planned.
Main results Eight studies (1 237 669 women) were included:
93 982 in the exposure group and 1 143 687 in the control
group. After adjusting for confounders, the incidence of PTB
was significantly higher in the group of women treated with
SSRIs compared with controls (i.e. both women with depression
but without SSRI exposure and women without depression)
(adjusted OR (aOR) 1.24, 95% CI 1.09–1.41). In the subgroup
analysis of studies in which controls were defined as women
with depression but without SSRI exposure during pregnancy, an
increased risk of PTB (6.8 versus 5.8%; OR 1.17, 95% CI 1.10–
1.25) in the SSRI group was found compared with controls (i.e.
depressed women treated with psychotherapy alone).
Conclusions Women who received SSRIs during pregnancy had a
significantly higher risk of developing PTB compared with
controls. This higher risk remained significant even when
comparing depressed women on SSRI with women not on SSRI.
Keywords Depression, drug, malformation, prematurity, preterm
birth.
Tweetable abstract Selective serotonin reuptake inhibitors may be
associated with preterm birth.
Please cite this paper as: Eke A, Saccone G, Berghella V. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a
systematic review and meta-analysis. BJOG 2016;123:1900–1907.
Introduction
Depression is a prevalent condition in pregnancy affecting
about 10% of women.1 Untreated antenatal depression is
associated with poor self-care during pregnancy, risk of
postpartum depression as well as risk of impaired mater-
nal–infant bonding when it persists into the postpartum
period.2 Maternal depression has also been associated with
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an increase in preterm births (PTB), low birthweight, fetal
growth restriction, and postnatal complications.2 Several
explanations for the concept that maternal depression may
contribute to PTB have been postulated: higher circulating
levels of inflammatory markers such as C-reactive protein
and the pro-inflammatory cytokines interleukin (IL)-1b,
IL-6 and tumour necrosis factor (TNF)-a; higher level of
placental CRH due to the increase of maternal pituitary-
adrenal stress hormones (e.g. ACTH, cortisol); higher risk
of bacterial vaginosis in women with maternal psychosocial
stress.3
Available treatments for depressive disorders are psy-
chotherapeutic interventions and antidepressant medica-
tions including selective serotonin inhibitors (SSRIs). SSRI
use during pregnancy has been associated with several fetal
and neonatal complications such as pulmonary hyperten-
sion,4,5 cardiac malformations and spontaneous abortion.6,7
However, so far the risk of PTB in women using SSRIs
during pregnancy is still a subject of debate.
The aim of this meta-analysis is to evaluate the risk of
PTB in cases of in utero exposure to SSRIs.
Methods
Eligibility criteria
This review was performed according to a protocol
designed a priori and recommended for systematic reviews
and meta-analyses.8 Two authors (A.E., G.S.) identified
studies by searching independently the electronic databases
MEDLINE, Scopus, ClinicalTrials.gov, the PROSPERO
International Prospective Register of Systematic Reviews,
EMBASE and the Cochrane Central Register of Controlled
Trials with the use of a combination of the following text
words: ‘depression’, ‘pregnancy’, ‘exposure’, ‘antidepres-
sant’, ‘SSRI’, ‘selective serotonin reuptake inhibitor’, ‘pre-
term birth’, ‘small for gestational age’ and ‘prematurity’
from inception of each databases until May 2015. No
restrictions as to language or geographic location were
applied.
Study selection
We included studies evaluating the effect of SSRIs exposure
in utero and pregnancy outcomes. All cohort and case-con-
trol studies were eligible to be included if they reported the
incidence of PTB after any exposure to SSRIs and had a
comparison group of unexposed pregnant women. We
included both studies in which controls were defined as ‘all
women’, i.e. without depression and without SSRI expo-
sure, as well as studies in which controls were defined as
women with depression but no SSRI exposure during preg-
nancy. Studies were excluded if they lacked the outcome of
interest (i.e. incidence of PTB). Studies without a control
group were also excluded.
Risk of bias
The risk of bias of the included studies was assessed via the
Methodological Index for Non-Randomized Studies (MIN-
ORS).9 Seven domains related to risk of bias were assessed
in each study: (1) aim (i.e. clearly stated aim), (2) rate (i.e.
inclusion of consecutive patients and response rate), (3)
data (i.e. prospective collection of data), (4) bias (i.e. unbi-
ased assessment of study end points), (5) time (i.e. follow-
up time appropriate), (6) loss (i.e. loss to follow-up), (7)
size (i.e. calculation of the study size).9 Review authors’
judgments were categorised as ‘low risk’, ‘high risk’ or ‘un-
clear risk of bias’.
Data abstraction
Two review authors (A.E., G.S.) independently assessed
inclusion criteria, risk of bias and data extraction. Dis-
crepancies were resolved by discussion with a third
reviewer (V.B.). Data from each eligible study were
extracted without modification of original data onto cus-
tom-made data collection forms. Data not presented in
the original publications were requested from the principal
investigators.
Primary and secondary outcomes were defined before
data extraction. The primary outcome was the incidence of
PTB (i.e. PTB <37 weeks). Secondary outcome included
birthweight and the incidence of respiratory distress syn-
drome (RDS). We planned to assess the primary outcome
in sensitivity analyses according to type of study, type of
SSRIs used and gestational age at antidepressant exposure.
We also planned to assess the incidence of PTB in an a
priori subgroup analysis of studies in which controls were
defined as women with depression but without SSRI
exposure during pregnancy.
Data analysis
The data analysis was completed independently by two
authors (A.E., G.S.) using REVIEW MANAGER 5.3
(Copenhagen: The Nordic Cochrane Centre, Cochrane Col-
laboration, 2014),8 and STATA command metandi (Stata
Corp. College Station, TX, USA: 2013). The completed
analyses were then compared and any difference was
resolved with review of the entire data and independent
analysis. Statistical heterogeneity between studies was
assessed using the Higgins I2 statistic.8 In case of statisti-
cally significant heterogeneity (I2 ≥ 50%) the random effect
model of DerSimonian and Laird was used to obtain the
pooled risk estimate, otherwise a fixed effect model was
planned.8 The summary measures were reported as odds
ratio (OR) or as mean difference (MD) with 95% confi-
dence interval (CI). A P-value <0.05 was considered statis-
tically significant. Potential publication biases were assessed
graphically using the funnel plot, and statistically using
Begg’s and Egger’s tests.
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For studies which reported both unadjusted and adjusted
risk for confounders statistically proven, we performed an
aggregate data meta-analysis using generic inverse variance
method in order to obtain the adjusted OR for the primary
outcome and for the secondary outcomes in the main anal-
ysis.8,10
The meta-analysis was reported following the Preferred
Reporting Item for Systematic Reviews and Meta-analyses
(PRISMA) statement.11 Before data extraction, the review
was registered with the PROSPERO International Prospec-
tive Register of Systematic Reviews (registration No.:
CRD42015027379) following the PRISMA guidelines for
protocols (PRISMA-P).12
Results
Study selection and study characteristics
The flow of study identification is shown in Figure S1.
Table 1 shows the characteristics of the included studies.
Eight studies including 1 237 669 women, were anal-
ysed.13–20 Of the 1 237 669 women included, 93 982 used
SSRIs as antidepressant during pregnancy, and 1 143 687
formed the non-exposed group (control group). Three
studies came from USA,17,18,20 two from Canada,15,16 and
the other three from Northern Europe.13,14,19 Five studies
used women with no depression or SSRI exposure as con-
trols.13–15,17,18 In the other three studies, controls were
defined as women with depression but without SSRI expo-
sure during pregnancy;16,19,20 these 97 303 controls were
prescribed no drugs and were treated with psychotherapy
alone.16,19,20 The quality of the studies included in our
meta-analysis was assessed by the MINORS tool for assess-
ing the risk of bias (Figure S2). Most of the included stud-
ies had low risk of bias in ‘aim’, ‘rate’, and ‘size’. Three of
them were prospective cohort studies,15,18,19 two retrospec-
tive,14,20 while the other three were large, high-quality pop-
ulation-based cohort studies.13,16,17 Regarding the type the
controls, all studies were judged as low risk of bias regard-
ing ‘contemporary groups’ and ‘baseline equivalence
group’.9 Two studies included only women who received
fluoxetine as SSRI,18,20 two only paroxetine,15,19 and the
others included women who received other SSRIs. Five
studies included women who received SSRIs only in the
first trimester,13,14,16,19,20 one only in the third trimester.15
Chambers et al.18 stratified data for gestational age, report-
ing data both for the first and the third trimester. Hayes
et al.17 did not report gestational age at antidepressant
treatment. The majority had PTB as primary outcome. In
all of the included studies, there was a high risk for bias
due to confounding by indication.
Risk of publication bias was assessed by visual inspection
of funnel plot, and the symmetric plot suggested no publi-
cation bias (Figure S3). Publication bias, assessed using
Begg’s and Egger’s tests, showed no significant bias
(P = 0.17 and P = 0.14, respectively).
Synthesis of results
The meta-analysis showed that the incidence of PTB was
significantly higher in the group of women treated with
SSRI than in controls (11.6 versus 5.2%; OR 1.45, 95% CI
1.24–1.68, Figure 1), even after adjusting for statistically
proven confounders, including maternal age, smoking, par-
ity, prepregnancy counselling, race and education (aOR
1.24, 95% CI 1.09–1.41, Figure 2). Neonates from women
who received SSRIs during pregnancy had a significantly
higher risk of RDS (3.7 versus 1.4%; OR 1.33, 95% CI
1.14–1.56, Figure 3; aOR 1.22, 95% CI 1.19–1.58) and sig-
nificantly lower birthweight (MD –117.12 g, 95% CI
125.99 to 108.24, Figure S4).
We found an increased risk of PTB in sensitivity analysis
of prospective cohort studies (OR 1.83, 95% CI 1.30–
2.59);15,18,19 of retrospective cohort studies (OR 1.51, 95%
CI 1.31–1.75);14,20 of population-based cohort studies (OR
1.14, 95% CI 1.11–1.17);13,16,17 of women who received
SSRIs in the first trimester (OR 1.67, 95% CI 1.25–
2.23);13,14,16,18–20 of women who received SSRIs in the third
trimester (OR 1.86, 95% CI 1.13–3.61);15,18 of studies in
which fluoxetine was used (OR 1.91, 95% CI 1.07–3.41);18,20
and in studies in which paroxetine was used (OR 2.07, 95%
CI 1.42–3.02).15,19 Women who received paroxetine had a
similar risk of PTB to those who received fluoxetine (OR
1.42, 95% CI 0.88–2.31). Women who received SSRIs in the
third trimester had a significantly higher risk of PTB com-
pared with those who received SSRIs only in the first trime-
ster (OR 4.17, 95% CI 2.75–6.30).
In subgroup analysis of studies in which controls were
defined as women with depression but without SSRI expo-
sure during pregnancy,16,19,20 we found an increased risk of
PTB in the exposed group (6.8 versus 5.8%; OR 1.17, 95%
CI 1.10–1.25; I2 = 0%) compared with controls (i.e.
depressed women treated with psychotherapy alone).
Discussion
Main findings
This meta-analysis showed that women who received SSRIs
during pregnancy had a significantly higher risk of develop-
ing PTB. This remained significant even when comparing
depressed women on SSRI versus depressed women not on
SSRI. This is important, as depression itself is associated
with preterm delivery.3 Neonates from women who
received SSRIs during pregnancy had a significantly higher
risk of RDS and significantly lower birthweight compared
with controls. The risk of PTB seems to be higher if the
SSRIs were given in the third trimester compared with an
earlier exposure.
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Comparison with existing literature
To date, most meta-analyses have found that exposure to
SSRI during pregnancy may be associated with several
pregnancy complications including neonatal pulmonary
hypertension and cardiac defects.4–7 These meta-analyses
did not analyse the correlation between SSRI and PTB. To
our knowledge, this is the first systematic review evaluating
this possible association. Other meta-analyses have reported
an association between antidepressants and PTB.21,22 Huy-
brechts et al. pooled data from 14 studies and found an
increased risk of preterm delivery in women taking antide-
pressants, including tricyclic and noradrenergic antidepres-
sant, during the second and third trimester of pregnancy.22
Strengths and limitations
The most important strength of our work rests on the
attention to potential confounding factors. Generic inverse
variance method was used to obtain the aOR for studies
which adjusted for statistically proven confounders. No
prior meta-analysis on this issue is as large, up-to-date or
comprehensive. The number of the included women is very
high. Most of the included studies had low risk of bias.
Subgroup analyses and sensitivity analyses were performed
to reduce the clinical heterogeneity within the studies.
Primary outcome was assessed in subgroup analysis of
studies in which controls were defined as women with
depression but without SSRI exposure during pregnancy,
which was the most clinical meaningful analysis.
Although meta-analytical techniques pool all available
data, limitations include those of the original articles. All
the included studies were cohort studies; no randomised
controlled trials were included in this systematic review
and this is a major shortcoming of this study. None of the
included studies stratified data for PTB aetiology, so data
regarding this outcome referred to both spontaneous and
indicated. This limitation places the biologic plausibility of
a drug–preterm delivery association in question, as the two
types of PTB have distinct aetiologies and pathogeneses.
There were different control groups and this point raises
the question of selection of the overall control group. Only
three studies adjusted for confounders and these may not
have been sufficient to control for a study of risk factors
for PTB.13,16,17 Even within the subgroup analysis, there
remained confounding by severity of depression that had
the potential to bias results significantly. Confounding fac-
tors that influence birth outcomes were variably controlled;
these potential confounders, such as poor prenatal care and
drug, nicotine and alcohol use, occur at a higher rate in
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Figure 2. Adjusted estimates forest plot for the risk of preterm birth in women treated with selective serotonin reuptake inhibitor. CI, confidence
interval; IV, independent variable; PTB, preterm birth; SE, standard error; SSRI, selective serotonin reuptake inhibitor.
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Figure 1. Unadjusted estimates Forest plot for the risk of preterm birth in women treated with selective serotonin reuptake inhibitor. CI, confidence
interval; M-H, Mantel-Haenszel test; PTB, preterm birth; SSRI, selective serotonin reuptake inhibitor.
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depressed than non-depressed women.23,24 Because SSRI
use occurs in the context of maternal depression, we were
not able to study the effects of SSRI exposure independent
of exposure to depression alone. This bias cannot be reli-
ably eliminated with a multivariable analysis. To avoid this
limitation we performed subgroup analysis of studies in
which controls were defined as women with depression but
without SSRI exposure during pregnancy. This subgroup
analysis concurs with the main analysis. However, only
three studies (113 526 women) were included; moreover,
restricting unexposed controls to depressed patients with-
out SSRI exposure does not remove the possibility of con-
founding by indication, as treatment groups were not
randomised. For example, it is possible that women in the
SSRI treatment group had more severe disease compared
with those who were not given medication, simply because
their physicians selected them for SSRI treatment. Based on
the characteristics of the included studies and the summary
statistics for heterogeneity there was a large amount of
both statistical and clinical heterogeneity. The studies vary
markedly by overall study design, analysis (e.g. some not
controlling for confounders), drug exposure timing, drug
type(s), and study population, especially with regard to
controls. This may impact the validity of the pooled results.
The statistical heterogeneity within the studies for the pri-
mary outcome was high (I2 = 86%). For this reason, ran-
dom effects models were used in most of the analyses
performed. Another major issue is the small OR (1.45 for
the primary outcome). The OR seems to be smaller in the
largest and best-designed studies (Figure 1).
Interpretation
There are many methods to treat depression during preg-
nancy.24 Many patients with mild-to-moderate depression
can be treated by psychosocial approaches such as individ-
ual and group psychotherapy instead of medication. Inter-
personal and cognitive behavioural psychotherapy have
been shown to be effective for depression in pregnant
women,25 and are recommended by The American College
of Obstetricians and Gynecologists (ACOG) and The
American Psychiatric Association (APA).24 Regarding
antidepressant treatment during pregnancy, SSRIs are the
most frequently prescribed drugs;26 physicians rarely use
monoamine oxidase inhibitors or tricyclic antidepres-
sants.26,27 However, there are no randomised controlled
trials of antidepressant drug efficacy in depressed pregnant
women.
The biological plausibility of our findings is not com-
pletely clear. With respect to prematurity, some studies
have suggested that maternal stress may increase the risk of
preterm delivery.28 Women who received SSRIs during
pregnancy in whom the rate of PTB was increased, may
have had more severe depression or anxiety and therefore
been at higher risk for PTB (i.e. bias due to illness sever-
ity). In this case, if the antidepressant treatment lessened
the effect of maternal depression, then in the absence of
treatment, the outcome of these pregnancies may have been
even worse. Alternatively, SSRIs could have affected the
outcome of PTB separately from the effect of depression.
Regarding birthweight, the findings of decreased birth-
weight are consistent with the results of a study in which
pregnant rats treated with fluoxetine delivered smaller
pups.29 Sometimes, the use of SSRIs during pregnancy is
inevitable. Untreated antenatal depression has been associ-
ated with suicidal tendencies, including death. Studies have
shown that stopping SSRI treatment in pregnant women
with a previous history of depression leads to relapse in the
majority of women. Untreated depression during pregnancy
has also been shown to be a strong risk factor for subse-
quent postpartum depression. Hence, in situations where it
may be necessary to use SSRIs in pregnancy (prior history
of severe antepartum or postpartum depression, current
history of suicidal tendencies in the setting of depression in
pregnancy, or in depressed patients dependent on high
doses of antidepressants in pregnancy), the decision to use
SSRIs during pregnancy must be weighed against the risks
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Figure 3. Forest plot for the risk of respiratory distress syndrome in women treated with selective serotonin reuptake inhibitor. CI, confidence
interval; M-H, Mantel-Haenszel test; RDS, respiratory distress syndrome; SSRI, selective serotonin reuptake inhibitor.
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of untreated depression and this risk/benefit ratio, includ-
ing the risk of preterm birth. This must be carefully dis-
cussed with the patient, and should ideally be done in
collaboration with the patient’s psychiatrist.
Conclusion
This meta-analysis showed that women who received SSRIs
during pregnancy had a significantly higher risk of develop-
ing PTB compared with controls. This higher risk remained
significant (17% increase in PTB) even when comparing
depressed women on SSRI versus depressed women not on
SSRI, which is the most clinical meaningful analysis.
In summary, these data warrant caution in the use of SSRIs
during pregnancy. Women should be informed about possible
risks of antidepressant medication during pregnancy. How-
ever, as other confounding cannot be excluded, these data
warrant further research on possible effects of SSRI on PTB.
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Is fetomaternal haemorrhage still a
major obstetric complication despite
new technologies management?
CORINNE HUBINONT, PROFESSOR IN OBSTETRICS, SAINT LUC UNIVERSITY HOSPITAL,
UNIVERSITE´ DE LOUVAIN, BRUSSELS, BELGIUM
.......................................................................................................................................................................
Fetomaternal haemorrhage (FMH) due tobleeding of fetal blood into the maternal cir-
culation can be responsible for unexplained still-
births and neonatal mortality. Severe FMH can
lead to fetal anaemia, cardiovascular failure, fetal
hydrops and subsequently to intrauterine death
but this is a rare condition with a prevalence of
0.3% (Maier et al. Arch Gynecol Obstet
2015;292:595–602). Before fetal monitoring and
ultrasound imaging to estimate fetal anaemia,
FMH diagnosis was based on Kleihauer, Braun
and Betke stain, measuring the acidity resistance
of fetal haemoglobin, and was possibly affected
by abnormal haemoglobin carrier status
(Pilkingston et al. J Obstet Gynaecol Br Cwlth
1966;73:909–16). In this study, blood trafficking
from fetus to the mother was found in normal
pregnancy blood samples, especially during
labour and after delivery (Figure 1). It was
increased in pre-eclampsia, artificial rupture of
the membranes, forceps delivery and manual
removal of the placenta.
Fetomaternal haemorrhage has been known
since the 1940s and even a small amount of
transplacental blood transfer can be responsi-
ble for haemolytic disease of the fetus and the
newborn (HDFN) whose mechanisms have
been reported previously (Hubinont. BMJ
1949;10:574–5). As maternal rhesus D anti-
bodies are responsible for the majority of
HDFN, clinical guidelines recommend preven-
tion by systematic administration of anti-D
immunoglobulin in RhD-negative pregnant
women at 28 weeks of gestation but also in all
situations at risk of FMH, such as miscarriage,
termination of pregnancy, invasive procedures
and external version. Anti-D is also given post-
natally to prevent RhD immunisation in subse-
quent pregnancies. A Dutch case–control study
has evaluated the risk factors for immunisation
despite an adequate anti-D prophylactic policy.
They found that assisted vaginal delivery or cae-
sarean section, post maturity, maternal red
blood cell transfusion and age were more fre-
quently associated with prophylaxis failure.
Overall, they found that 50% of the RhD
immunisation cases were due to either a
massive FMH or to insufficient anti-D
administration (Koelewijn et al. BJOG
2009;116:1307–14).
The Kleihauer, Braun and Betke stain test is
still used for diagnosis even if flow cytometry
is the reference standard for FMH quantifica-
tion. Management using ultrasound and inva-
sive fetal procedures improved FMH prognosis
over the last 40 years. Fetal anaemia can be
detected by Doppler peak systolic velocity
measurement of the middle cerebral artery
with an excellent sensitivity and specificity
(Mari et al. N Engl J Med 2000;342:9–14).
Management of fetal anaemia by intrauterine
fetal intravascular blood transfusion was first
described in 1981 (Rodeck et al. Lancet
1981;1:625–7) and is associated with a high
perinatal survival rate reaching 90%. However,
despite this management, massive FMH respon-
sible for stillbirth still occurs. In conclusion, FMH
is a rare condition possibly associated with fetal
anaemia. HDFN could be prevented in Rhesus-
negative patients with anti-D prophylaxis. Fetal
intrauterine transfusion improved FMH progno-
sis but did not suppress its mortality rate in sev-
ere cases.
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Figure 1. Quantification of fetal red cells in maternal blood in ABO compatible and
incompatible women during pregnancy, labour and after placental delivery. Reproduced
from Pilkington, R. et al (1966), Foetal-maternal transfusion and rheus sensitization. BJOG
1966;73:909–916. doi:10.1111/j.1471-0528.1966.tb06113.x.
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